Metabolic & Endocrine
Hyperparathyroidism
5
Pipeline Programs↗
1
Active Trials↗
3
Companies Involved↗
Hyperparathyroidism is an early-stage landscape with 5 programs across 3 companies. The most active players are Amgen, AbbVie, Alnylam Pharmaceuticals. 1 therapy is approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 31
Approved1
Analysis
Trial Status
2
clinical trials
Completed1 · 50%
Recruiting1 · 50%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)